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ABSTRACT
Cytomegalovirus (CMV) disease-related mortality in allogeneic hematopoietic stem cell transplant (HSCT)
recipients has dramatically declined because of ganciclovir prophylaxis and preemptive therapeutic strategies.
However, ganciclovir has not improved overall survival in randomized studies despite effectively preventing
overt CMV disease. Moreover, recurrent posttransplant CMV antigenemia, associated with prolonged ganci-
clovir exposure, is a predictor of increased relapse of malignancy. We examined the hypothesis that ganciclovir
itself may have a negative impact on immune reconstitution by testing the effect of ganciclovir on normal
human lymphocytes in vitro. T-lymphocyte activation and proliferation, as measured by PHA-induced 3H-
thymidine uptake, was greatly reduced at therapeutic concentrations of ganciclovir (10 g/mL) but not for
foscarnet (300 M/L). Moreover, ganciclovir impaired bromodeoxyuridine incorporation in proliferating
lymphocytes, but did not impair lymphocyte survival or induce lymphocyte apoptosis. Collectively, these
results show that ganciclovir suppresses T-lymphocyte proliferation in vitro by inhibiting DNA synthesis; with
implications for T-lymphocyte function following allogeneic BMT.
© 2007 American Society for Blood and Marrow Transplantation
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aNTRODUCTION
Cytomegalovirus (CMV) disease has historically
een a major contributor to mortality after allogeneic
ematopoietic stem cell transplantation (HSCT) [1].
ith the introduction of ganciclovir, prophylactic,
nd preemptive antiviral strategies have greatly re-
uced the incidence of breakthrough CMV organ dis-
ase and mortality to about 5% [2-4]. Despite impres-
ive reduction in CMV-related mortality, several
tudies have shown that CMV seropositive patients
ontinue to have higher mortality than patient-donor
airs who are both CMV seronegative [5-9]. Reasons
ited for this observation include: (1) predisposing
raft-versus-host disease (GVHD); (2) antiviral toxic-
ties (myelosuppression with ganciclovir; renal dys-
unction with foscarnet and cidofovir); (3) infections Telated to ganciclovir-induced neutropenia; and (4)
MV itself disabling immune reconstitution.
Ganciclovir is a nucleoside analog of guanosine
hat competitively inhibits the incorporation of dGTP
y viral DNA polymerase [10]. However, this effect is
nly partially speciﬁc for the viral polymerase because
anciclovir also inhibits DNA synthesis in hematopoi-
tic progenitors [11]. Although cytopenias are a well-
ecognized complication of ganciclovir therapy, the
ossibility of direct lymphocyte inhibition has escaped
ttention, perhaps because ganciclovir is usually em-
loyed in subjects with a preexisting quantitative or
ualitative impairment of cellular immunity. Ganci-
lovir has been previously shown to inhibit in vitro
roliferative responses to cytomegalovirus antigen
nd to phytohemagglutinin by greater than 50% [5].
he purpose of our study is to deﬁne the mecha-
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M. Battiwalla et al.766ism by which ganciclovir inhibits T cell prolifera-
ion.
ATERIAL AND METHODS
eripheral Blood Mononuclear Cells (PBMCs)
Blood samples were obtained from consenting
ormal adult volunteers and PBMCs extracted by
icoll-Paque centrifugation. This study was approved
y the Roswell Park Cancer Institute Review Board.
ymphocyte Proliferation Assays
Peripheral blood mononuclear cells were sus-
ended in RPMI-CM supplemented with heat-inacti-
ated 10% AB-serum at a concentration of 5  105
ells/mL. Lymphocytes were stimulated with 10%
HA (T-Stim, BD Biosciences, Bedford, MA), or with 5
L/mL cytomegalovirus lysate (ABI, Columbia, MD),
nd incubated for 5 days at 37°C with 5% CO2. Ganci-
lovir (Roche, Nutley, NJ), foscarnet (Abbot Labs, Chi-
ago, IL) or tacrolimus (Astellas, Tokyo, Japan) were
dded to achieve ﬁnal concentrations equal to their peak
herapeutic concentrations achieved in vivo (10 g/mL,
00 M/L, and 10 ng/mL, respectively), and concen-
rations 5-fold lower or 5-fold higher. One hundred
icroliters of cellular suspension were placed in qua-
ruplicate in wells of a 96-well plate. Lymphocyte
roliferation in response to these stimulators was as-
essed by a standard [3H] Thymidine uptake assay.
xperiments were performed on PBMCs collected
rom 3 different healthy voluntary donors on 2 sepa-
ate occasions.
urvival and Apoptosis
The survival of unstimulated PBMCs in the
resence or absence of ganciclovir was assessed us-
ng an automated cell counter (Hematology System
DVIA120, Bayer). Fresh PBMCs were incubated in
PMI-CM supplemented with 10% AB-serum at
7°C with 5% CO2 for 4 days. Cells were counted for
otal and % lymphocytes on days 0, 1, 3, and 4.
Apoptosis was assessed using the Raji Lympho-
lastic Leukemia cell line and with normal human
BMCs. Raji cells (unstimulated) or PBMCs induced
o proliferate with 10% PHA (T-Stim, BD Bio-
ciences), or with 5 L/mL Epstein Barr Virus lysate
ABI), were treated with varying concentrations (25 or
25 g/mL) and durations (12, 24, and 48 hours) of
anciclovir. HD10 antibody (10 mg/mL for 2 hours)
as used with the Raji cells as a positive control. Cells
ere stained with Annexin V-FITC and Propidium
odide (PI) and analyzed by ﬂow cytometry. (BD Bio-
ciences apoptosis kit).
ell Cycle Analysis
Resting or PHA-stimulated PBMCs, were incu-
ated for 5 days. Ganciclovir (30-120 g/mL) was sdded after days 1, 3, or 4. At the end of a 5-day
ncubation, cells were pulsed with 20 M of bromode-
xyuridine (BrdU) for 30 minutes. Cell cycle analysis
as performed using the BrdU-Flow Kit using man-
facturer’s instructions (BD-Pharmingen, San Diego,
A). The experiment was repeated using cells from
different individuals on separate occasions for con-
rmation.
ESULTS
ymphocyte Proliferation
Lymphocyte proliferation experiments demon-
trated dose-dependent inhibition of thymidine up-
ake by ganciclovir in all individuals (Figure 1).
owever, foscarnet did not inhibit lymphocyte pro-
iferation even at 1500 M/L, 5-fold the therapeutic
oncentration. Tacrolimus uniformly suppressed pro-
iferative responses at all concentrations (2-50 ng/
L). The extent of inhibition by GCV when lympho-
ytes were stimulated with CMV antigen was 59.2%
95% conﬁdence interval [CI], 51.9-66.5%) (P  .001
y the paired t-test) compared with PHA-stimulation
7% (95% CI, 27.5-47.2%P (P  .001 by the paired
-test). The difference between the inhibition of pro-
iferation using CMV antigen and PHA as stimuli was
tatistically signiﬁcant.
urvival and Apoptosis Assays
Ganciclovir had no effect on the survival of un-
timulated PBMCs, either total or % lymphocytes at
ny time point compared to controls. Ganciclovir did
ot induce apoptosis of Raji cells or of stimulated
ormal peripheral blood lymphocytes even at 5-fold
he therapeutic concentration (Figure 2).
ell Cycle Analysis
Bromodeoxyuridine incorporation into PHA-stimu-
ated lymphocytes was greatly reduced by ganciclovir.
eduction of S-phase BrdU incorporation ranged be-
ween 56%-64%. The effect was not seen for periods of
ncubation with ganciclovir for 24 hours or less and was
ronounced for ganciclovir exposures greater than 72
ours (Figure 3).
ISCUSSION
We found that ganciclovir directly inhibited T cell
roliferation induced by various stimuli at therapeutic
oncentrations in a dose dependent fashion as previ-
usly reported. We observed that CMV-antigen
riven lymphocyte proliferation was inhibited to a
reater extent than PHA-induced proliferation. This
s probably related to the relative strength of the
timuli; powerful stimuli like PHA can overwhelm the
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Ganciclovir Inhibits Lymphocyte DNA Synthesis 767oderate immunosuppressive property of ganciclovir.
anciclovir did not reduce survival of unstimulated
BMCs, nor did it induce apoptosis. We demonstrate
hat the mechanism by which ganciclovir inhibits
cell proliferation is by inhibition of DNA synthesis.
Ganciclovir triphosphate competitively inhibits
he incorporation of deoxyguanosine-triphosphate
dGTP) into viral DNA, resulting in the intranuclear
ccumulation of short DNA fragments [12,13]. Selec-
ivity for viral DNA polymerase relates to the 10-
old higher concentration achieved in CMV-infected
ells [14]. The inhibitory effect of ganciclovir on
rdU incorporation demonstrated in the present
tudy can be interpreted in light of the above mecha-
ism as evidence that ganciclovir affects lymphocyte
unction by impairing DNA synthesis at the therapeu-
ic concentrations achieved in vivo.
Ganciclovir is the traditional ﬁrst-line agent for
MV reactivation, partly because of its familiar and
elatively favorable safety proﬁle. However, in a large
andomized multicenter trial of 203 patients compar-
ng foscarnet with ganciclovir as preemptive therapy
or CMV-reactivation, foscarnet was shown to be
qually effective with no greater toxicity [15]. Long-
igure 1. Effect of ganciclovir, foscarnet, and tacrolimus on 3H in
ntigen (B). Values are medians; error bars represent SEM. The
xperimental results of each quadruplicate by the average of the unerm survival data were not presented in that study. In rontrast to ganciclovir, foscarnet directly inhibits
NA polymerase in a noncompetitive manner; selec-
ivity for viral DNA polymerase results from its 100-
old greater inhibitory effect on viral rather than cel-
ular DNA polymerase [16,17]. This ﬁnding may
xplain the neutral effect of foscarnet in the prolifer-
tion assay in the present study.
The consequences of the immunomodulatory ef-
ect of ganciclovir are potentially serious in the HSCT
etting. Ultimately, suppression of CMV reactivation
equires the expansion of donor-derived CMV-
peciﬁc T cells from the stem cell graft [18-20]. Pro-
onged antiviral therapy is known to impair the acqui-
ition of full CMV immunity by suppressing antigen
roduction resulting in late CMV reactivation [21].
lthough this effect is not conﬁned to ganciclovir, the
nhibition of lymphocyte proliferative responses by
anciclovir could contribute to the late CMV reacti-
ations. Of greater concern is the potential impair-
ent of the graft-versus-leukemia response account-
ng for the higher incidence of relapse seen in patients
ith multiple reactivations of CMV [22]. The impact
f the immunosuppressive effect of GCV relative to
raditional risk factors for disease relapse such as the
tion in normal human PBMCs stimulated with PHA (A) or CMV
lation index (SI) was determined by dividing the average of the
ated cells on the same plate.corpora
stimuemission status prior to transplant, extent of immune
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M. Battiwalla et al.768uppression, and the presence of GVHD remains to
e conclusively determined.
The previously unsuspected impairment of im-
une reconstitution by ganciclovir may explain an-
ther inconsistency in the HSCT literature. Ganci-
lovir is several-fold more active than acyclovir in
itro and in vivo against CMV. Prophylactic and pre-
mptive ganciclovir have resulted in reduced CMV-
nfection related mortality, but no beneﬁt on overall
urvival (OS). However, high-dose acyclovir prophy-
axis has led to improved OS, although it is less effec-
ive than ganciclovir in suppressing CMV reactivation
23,24]. Although this is an intriguing observation,
igh-dose acyclovir has not been compared in a ran-
omized fashion to ganciclovir.
In conclusion we show that ganciclovir exerts sig-
igure 2. Effect of ganciclovir on apoptosis. Raji cell line with media
r stimulated by PHA or EBV-antigen with varying concentrationiﬁcant inhibitory effects on lymphocyte proliferation Cy inhibiting DNA synthesis. Further studies are re-
uired to determine whether these in vitro effects
ranslate into impaired immune reconstitution in pa-
ients. Medications should be carefully evaluated for
mmunological effects in the clinical practice of
SCT.
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